Abstract. Nicotinamide N-methyltransferase (NNMT) has been proposed as a link between the environmental and genetic factors of Parkinson disease (PD). Therefore, we explored the hypothesis that high levels of NNMT expression may predispose to the development of PD. Regions of high mRNA expression were shown in the spinal cord, medulla, and temporal lobe, with lowest expression in the cerebellum, subthalamic nucleus, and caudate nucleus. Using 2 NNMT antibodies, the protein was shown to be expressed in multipolar neurons in the temporal lobe, caudate nucleus, and spinal cord, granular neurons of the cerebellum, dopaminergic neurons in the substantia nigra, and in the axons of the third nerve. Expression of NNMT was compared in PD and non-PD control cerebella and caudate nucleus. PD tissue exhibited significantly increased levels of NNMT protein and activity. PD disease duration was inversely correlated with the level of expression in cerebellum. This is the first demonstration that patients with PD have higher levels of NNMT activity and protein in brain tissue than those without PD and that NNMT expression is associated with neurons that degenerate in PD.
INTRODUCTION
Nicotinamide N-methyltransferase (NNMT, EC 2.1.1.1) catalyses the N-methylation of nicotinamide (1) (2) (3) , various closely related structural analogues such as thionicotinamide and 3-acetylpyridine (4), and poor structural analogues such as quinoline, isoquinoline, and 1,2,3,4-tetrahydroisoquinoline to form positively charged pyridinium ions (5-7). Liver NNMT is an S-adenosylmethionine-dependent cytosolic enzyme (1) with a molecular weight of approximately 27 kDa (5, 8) . The human NNMT gene has been localized to chromosome 11q23.1, is 16.5 kbp in length, and comprises 3 exons and 2 introns with an open reading frame of 792 base pairs which codes for a protein of 264 amino acids (8, 9) . The pharmacogenetics of human liver NNMT have been well described. A large pharmacological study of NNMT activity showed a bimodal frequency distribution with 25% of samples in a high activity subgroup (10) . This distribution is due to variations in NNMT protein levels and not as a result of a coding region polymorphism (11) .
N-methylation usually results in the detoxification of the substrate. However, paradoxically this biotransformation has been shown to increase the toxicity of some compounds, e.g. the N-methylation of 1,2,3,4-tetrahydroisoquinoline to the dopaminergic neurotoxin N-methyl-1,2,3,4-tetrahydroisoquinoline (4) . It has been suggested that the presence of NNMT activity in the brain may be a factor in the etiology of Parkinson disease (PD), as the products of the N-methylation of pyridines by NNMT are related to another well-characterized dopaminergic neurotoxin methylphenylpyridinium ion (12) . Recent interest in the potential roles of NAD in cellular signaling pathways suggests a potential role for NNMT in the regulation of various brain cellular pathways (13) .
In this work we set out to explore the hypothesis that patients with PD have higher levels of NNMT in the brain than normal subjects. The rationale for this was that higher levels of the enzyme would generate higher concentrations of neurotoxic methylpyridinium compounds. Because the only available tissue was postmortem material from PD patients who have experienced years of illness and because substantial neuronal loss must have occurred in the substantia nigra, if NNMT is expressed in neurons, increased nigral expression in PD would be extremely difficult to detect. Therefore, we investigated 2 regions not greatly affected by the disease (cerebellum and caudate nucleus) and for which high quality tissue was readily available. This enabled expression in control and disease subjects to be compared under circumstances where the direct effect of the disease was minimal. The hypothesis presupposes that NNMT is expressed in neurons and that expression of the enzyme is widespread throughout the brain. In order to establish these points, a series of preliminary studies was carried out on tissue from different individuals. These involved a) determination of regional expression of NNMT mRNA in the normal human central nervous system using Northern blotting, b and c) confirmation of NNMT expression by Western blotting and activity assay, respectively, d) elucidation of cell specific expression by immunohistochemistry, results being compared with those in the liver (positive control tissue) and renal cortex (negative control tissue), and finally e) determination of the stability of NNMT in brain tissue. Having determined optimal experimental conditions and confirmed widespread expression of the enzyme in the central nervous system (CNS), a more wide-ranging comparison of enzyme expression in control and parkinsonian brains was carried out. This consisted of comparison of NNMT protein expression (Western blotting) and enzyme activity in 2 regions not greatly affected by PD, cerebellum and caudate nucleus. Secondly, immunohistochemistry was used to compare neuronal expression of NNMT in normal and parkinsonian cerebellum. Finally, a limited immunohistochemical study was carried out to compare neuronal NNMT expression in substantia nigra and oculomotor (third) nerve region in the disease and control subjects.
MATERIALS AND METHODS
All chemicals were of the highest purity available and were obtained from Sigma, Poole, UK, unless otherwise stated. Secondary antibodies and streptavidin peroxidase conjugate used for immunohistochemistry were obtained from The Binding Site Ltd., Birmingham, UK. Goat peroxidase-anti-peroxidase (PAP) was obtained from Dako Ltd., Cambridge, UK. VectaShield mounting medium was obtained from Vector Laboratories (Burlingame, CA). Two anti-NNMT antibodies against linear epitopes of the NNMT protein (NNMT a1 sequence DYSDQNLQELEKWLKKEPEA; NNMT a2 sequence CDLE-GNRVKGPEKEEKLRQA) used in the immunochemical investigations described below were produced and affinity-purified as described previously (11, 14) . Preabsorption of the NNMT antibodies was carried out using antigenic peptide (Alta Bioscience Ltd., Birmingham, UK) as previously described (14) . All studies on regional and nigral NNMT expression used both anti-NNMT antibodies, whereas only antibody 1 was used for the cerebellar studies.
Preliminary Experiments
Regional Expression of NNMT mRNA: Human brain multiple tissue Northern blots were obtained from Clontech (Clontech Laboratories Inc., Basingstoke, UK). NNMT mRNA was detected by probing with a 32 P-labelled NNMT cDNA probe prepared as described previously (11), followed by stripping and reprobing with a 32 P-labelled ß-actin cDNA probe (Clontech). Densitometric analysis of the bands obtained was performed using a laser densitometer and the ratios of NNMT to ß-actin were calculated to allow inter-regional comparisons to be made.
NNMT Protein Expression Determined by SDS-PAGE/Western Blotting:
To confirm the results of the Northern blotting study at the protein level, tissue from 4 brain regions was investigated at the translational level. Normal human temporal lobe was obtained from the Department of Pathology, University of Birmingham, UK, from a 55-yr-old female patient undergoing surgical treatment for epilepsy. It was classed as a pathologically normal tissue because it was taken from an unaffected region and removed only for access. The sample was immediately frozen in liquid nitrogen. Normal human spinal cord was obtained as a postmortem sample from the Department of Pathology, University of Birmingham from a 55-yr-old male patient who had died of a pulmonary embolus and dilated cardiomyopathy. The postmortem interval was 2 days. Normal caudate nucleus and cerebellum were obtained from the Parkinson's Disease Society Brain Research Centre (PDBRC), Institute of Neurology, University College London, UK. All brains used here and in subsequent analyses were subjected to a full neuropathological examination by the PDBRC, who found no evidence of other concomitant disease or pathology. As a confirmatory exercise, expression in an enzyme-positive (liver) and enzyme-negative (renal cortex) was investigated. Normal human liver and kidney were obtained from the Liver Unit of the Queen Elizabeth Hospital, Birmingham, UK as flash-frozen samples taken from a traffic accident victim acting as a donor for juvenile transplants. In this latter case the postmortem interval was less than 24 h.
Homogenates were prepared by homogenizing in 50 mM Tris-buffered saline, pH 7.4 (TBS) and centrifuging the homogenate at 600 ϫ g for 10 min. Protein concentration was determined using the method of Bradford (15) . Homogenates (20 g/well) were subjected to either analysis for NNMT activity as described below or electrophoresed as per the method of Laemmli (16) on a 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and subjected to Western blotting as previously described (16) , with the modification of using primary antibody dilution of 1:500 overnight at 4ЊC.
Expression of NNMT Activity: The activity of NNMT of the homogenates described above was determined in triplicate for each sample using a radioisotope assay based upon the method of Rini et al (10) . Homogenate was diluted 1:10 (v/v) with bovine serum albumin (BSA, 2 mg/ml) supplemented 5 mM Tris HCl, pH 7.2 and 100 l was transferred to a 15 ml polypropylene tube. One hundred fifty mM nicotinamide in dimethylsulphoxide or dimethylsulphoxide alone (10 l) was added and the reaction initiated by the addition of a solution comprising 500 mM Tris HCl, pH 7.2, 150 M S-adenosylmethionine and S-adenosyl-L-[methyl-
3 H]methionine (12.5 Ci/ml, Amersham, Rainham, UK). The reaction was incubated at 37ЊC for 20 min and then terminated by the addition of 200 l of 500-mM borate buffer, pH 10. Eight hundred fifty mM heptanesulphonic acid (100 l) was added and vortexed for 10 s, after which the radioactive product was extracted into organic phase by the addition of a 3:2 solution of isoamyl alcohol: toluene (5 ml) followed by centrifugation at 400 ϫ g for 10 min. An aliquot (2 ml) of the organic phase was mixed with an equal volume of scintillation fluid (OptiPhase Hisafe 3, LKB Scintillation Products, Leicester, UK) and the radioactivity was counted using a beta counter. Results were corrected for quenching and counting efficiency (62%) and were expressed as units (the formation of 1 nmol of 1-methylnicotinamide per hour per mg protein).
Cellular Localization of NNMT:
The cellular localization of NNMT in single samples of normal temporal lobe, spinal cord, normal and parkinsonian caudate nucleus, and 2 normal and parkinsonian cerebella and midbrain sections containing both substantia nigra and third nerve (obtained from the PDBRC) was determined using the method of Sternberger et al (17) . In addition, immunohistochemistry was carried out on 2 non-central nervous system tissues; liver, which is known to express the enzyme, and the renal cortex, in which the enzyme activity was undetectable (18) . These served as positive and negative control tissues, respectively. Anti-NNMT and other primary antibodies were diluted in 25 mM Tris-buffered saline, pH 7.4 supplemented with 1% (w/v) BSA. Sections of frozen tissue (5 m) were fixed briefly in icecold acetone, demyelinated in chloroform then blocked for peroxidase activity after which the brain tissues only were microwaved at 95Њ-99ЊC for 30 min in a 10 mM citrate buffer, pH 6.0. Protein binding sites were blocked using normal donkey serum (1:10, The Binding Site Ltd.) and NNMT expression was detected as described in Table 1 . These conditions were optimized in order to produce the highest degree of contrast between staining arising as a result of antibody binding and any endogenous pigmentation that may be present.
The cellular localization of NNMT in both the cerebellum and the substantia nigra was clarified using anti-glial fibrillary acidic protein (GFAP, 1:100, The Binding Site Ltd.) and antityrosine hydroxylase (THO, 1:10, Novo Castra Laboratories Ltd., Newcastle-upon-Tyne, UK) in single-labeling experiments to determine whether the cells expressing NNMT were neuronal or glial cells. Because THO is not expressed in the cerebellum, incubation of this region with anti-THO antibody mainly served as an additional immunohistochemical negative control. Briefly, sections were fixed, blocked for peroxidase activity, microwaved, incubated with donkey serum (1:20) , and probed for THO and GFAP expression as described in Table 1 .
Stability of NNMT Protein upon Storage:
To investigate the stability of the enzyme under storage, 3 snap-frozen spinal cord samples taken from patients who had not died of PD were obtained from the PDBRC as outlined in Table 2 . Samples of each spinal cord sample were stored at either 4ЊC or Ϫ20ЊC for 0, 12, or 24 h prior to homogenization. Samples (n ϭ 3 for each storage condition) were assayed in triplicate for enzyme activity as described above, making a total of 18 assays for each subject sample. Further samples were electrophoresed, blotted to nitrocellulose, and probed with anti-NNMT antibodies as described above. Band detection was done using a combination of donkey-anti-sheep IgG conjugated to horseradish peroxidase (The Binding Site Ltd., 1:1000, 1 h room temperature) followed by electrochemiluminescence (Amersham Pharmacia Biotech) as per manufacturer's instructions. Bands were quantified using laser densitometry (n ϭ 3 per band) and expressed as percentage of zero time.
Quantitation of Expression of NNMT in the Brains of PD and Non-PD Subjects
Flash-frozen normal and parkinsonian cerebellum and caudate nucleus were obtained from the PDBRC as approximately 50-mg pieces of tissue from which protein was isolated for SDS-PAGE/Western blotting and NNMT activity assay as described above. Additionally, normal and parkinsonian cerebella and substantia nigra were obtained as pre-cut 12 m sections on glass slides for immunohistochemistry. Clinical data on the subjects (postmortem interval, pH of cerebellum, age of death, disease duration [parkinsonian subjects only]) relating to the 25 donors were also obtained; 16 non-PD control and 9 PD as outlined in Table 3 . Postmortem intervals were generally below 40 h; however, 1 sample had a postmortem interval of 79 h 30 min. The pH of this brain was within acceptable limits (greater than 6.25), as pH has been shown to be a reliable indicator of agonal state and mRNA preservation (19) .
Western Blotting and Enzyme Activity of NNMT in the Caudate Nucleus and Cerebellum
The expression of protein and enzyme activity in the caudate nucleus and cerebellum of all 25 PD and non-PD cases were investigated as described above.
Immunochemical Quantitation of NNMT Expression in
Cerebellum and Substantia Nigra
The quantitation of NNMT in the cerebellum of all 25 PD and non-PD cases was investigated using immunohistochemistry as described in Table 1 . The granular layer of each section was counted independently by 2 investigators in 20 random areas, counting both immunostained and unstained cells in a standard unit area as visualized using a standard 10 ϫ 10 eyepiece graticule (Pyser-SGI Ltd, Kent, UK). The ratio of stained to total neurons (irrespective of the apparent level of staining) was determined and the results reported as percentage expression.
The quantitation of NNMT in the substantia nigra was determined using immunofluorescence as described in Table 1 . Tissue was only available for 7 control and 9 parkinsonian subjects. Neurons in 4 identically sized areas for each subject were counted independently by 2 researchers as for the cerebellum. Some substantia nigra slides were counterstained with propidium iodide (1:10) for 15 min at room temperature prior to mounting.
Statistical Analysis
All statistical analyses carried out using the Instat statistics package (GraphPad, San Diego, CA) were as follows: i) Kruskal-Wallis non-parametric ANOVA and Dunn's Multiple Comparison test was used for assessing the storage properties of tissue; ii) comparisons of data from parkinsonian and control subjects were analyzed using either the Mann-Whitney U nonparametric test or the Student t-test; and iii) the significance of trends was determined using Spearman rank correlation. Results were considered significant at the 5% level.
RESULTS

Preliminary Experiments
Regional Expression of NNMT mRNA Expression: Table 4 shows the ratio of NNMT:ß actin densities in 16 regions of 1 human brain. Differences in NNMT mRNA expression were seen in the various regions. The highest levels of NNMT expression were in the spinal cord, medulla, and temporal lobe. The lowest levels of expression were in the cerebellum, caudate nucleus, and subthalamic nucleus. Detectable levels of the NNMT mRNA transcript were found in the substantia nigra.
SDS-PAGE/Western Analysis of Tissue
Homogenates: NNMT was expressed in the spinal cord, temporal lobe, and liver. Highest expression was in the liver, followed by the spinal cord and then temporal lobe. NNMT was not expressed in human kidney cortex (data not shown). Caudate nucleus and cerebellum also expressed NNMT; the results are shown in Table 5 . Both antibodies gave identical results.
NNMT Activity of Tissue Homogenates: NNMT activity was in accord with the expression of protein, with specific activities of 15.42 Ϯ 0.98 in the liver, 0.25 Ϯ 0.09 in the spinal cord, and 0.11 Ϯ 0.12 in the temporal lobe, respectively. No activity was detected in the kidney homogenate. Results for caudate nucleus and cerebellum are shown in Table 5 .
Cellular Localization of NNMT Protein:
Both anti-NNMT antibodies gave identical results in the studies present below. Figure 1 shows the localization of NNMT in the temporal lobe (Fig. 1A) compared with no primary antibody control (Fig. 1B) and non-immune sheep serum (Fig. 1C) . Staining was localized to the cell bodies of multipolar neurons and to the immediate area of the axonal and dendritic processes originating from the cell body. Preabsorption of the antibodies with antigenic peptide removed all evidence of staining (Fig. 1D) . Preabsorption of the antibodies with the non-complementary antigenic peptide had no effect upon staining (data not shown). Figure 2 shows the localization of NNMT in the spinal cord ( Fig. 2A ) compared with no primary antibody control (Fig. 2B ) and non-immune sheep serum (Fig. 2C) . Staining was expressed in the multipolar neurons. Preabsorption of the antibodies with antigenic peptide removed all evidence of staining (Fig. 2D) . Preabsorption of the antibodies with non-complementary antigenic peptides had no effect upon staining (data not shown).
Temporal Lobe
Spinal Cord
Cerebellum Figure 3A -F shows the immunohistochemical staining for NNMT in both non-PD (Fig. 3B, C) and PD (Fig.  3D, E) cerebellum. Localization was limited overwhelmingly to the neurons of the granular layer, with staining evident only to a low degree in the molecular layer. No staining was evident in the white matter under any of the conditions used. No staining was evident when primary antibody was replaced with antibody diluent only (Fig.  3A) . Preabsorption of the antibody with antigenic peptide removed all staining (Fig. 3F) . Cerebella from PD subjects showed a greater degree of staining than those cerebella from the non-PD subjects. Figure 3M layer. No staining was observed in the majority of the granular layer, with limited expression in the molecular layer. GFAP staining was not associated with cell types that expressed NNMT. Expression of GFAP occurred in the same cell type in both PD and non-PD cerebellum. There was no staining associated with THO in the cerebellum (data not shown).
Midbrain Sections Containing Substantia Nigra and
Third Nerve Figure 3G -L shows the typical expression of NNMT in the substantia nigra/third nerve region of non-PD (Fig.  3G-I ) and PD (Fig. 3J-L) subjects. In control subjects, NNMT was present in pigmented dopaminergic neurons of the substantia nigra and was not evident in glial cells (Fig. 3G, H) . Expression was present in the cell body and the dendritic processes of the neurons. In the substantia nigra of subjects who had died from PD, expression was also neuronal but few pigmented neurons could be seen (Fig. 3J, L) . Expression appeared limited to the cell bodies because axonal processes were absent or so small as to be difficult to detect. Preabsorption of the primary antibody removed all evidence of staining (data not shown). Staining was also observed in the third nerve-non-PD, with staining present in the cell body and along the length of the axonal process (Fig. 3I) , however staining was barely detectable in this region in the PD material (Fig.  3K) . Figure 3O shows the typical localization of dopaminergic neurons in the normal substantia nigra as shown using THO staining. Staining was present in the cell body, the axon, and the dendritic processes of the dopaminergic neuron. THO expression was associated with those cell-types that expressed NNMT. Figure 3N shows the typical localization of glial cells (astrocytic in morphology) in the substantia nigra as shown using GFAP staining. Expression of GFAP occurred in the same cell type in both the PD and non-PD substantia nigra. GFAP staining was not associated with the cell types that expressed NNMT.
Caudate Nucleus
There was limited expression of NNMT in the cell bodies of neurons and faint expression could be seen in projections from these (data not shown). There was no obvious qualitative difference in the expression of NNMT between the PD and non-PD samples.
Liver Figure 4 shows the localization of NNMT in human liver (Fig. 4A ) compared with no primary antibody control (Fig. 4B ) and non-immune sheep serum (Fig. 4C) . NNMT was expressed in the periportal region only. In the portal triad, staining was present in the epithelia of the bile duct and the hepatic artery. Preabsorption of the antibodies with antigenic peptide removed all evidence of staining (Fig. 4D) . Preabsorption of the antibodies with non-complementary antigenic peptide had no effect upon staining (data not shown).
Kidney
No NNMT expression was detectable in the kidney cortex (data not shown).
Stability of NNMT Protein upon Storage: There was no significant effect of storage upon the activity and protein stability of NNMT (p Ͼ 0.05 for each storage condition using a combination of Kruskal-Wallis non-parametric ANOVA and Dunn's Multiple Comparisons tests). Table 5 summarizes the expression of NNMT in the caudate nucleus and cerebellum using an activity assay and densitometric analysis of the Western analysis. The levels of enzyme Abbreviations: n ϭ neuron cell body; d ϭ dendritic processes; a ϭ axonal process. Magnification, ϫ400. Scale bar ϭ 25 m. M, N: Typical expression of glial cells in the cerebellum and substantia nigra respectively. Samples were probed for GFAP using anti-GFAP (1:100) for 1 h at room temperature followed by donkey-anti-sheep IgG biotin conjugate (1:50) followed by streptavidin-conjugated horseradish peroxidase (1:50) for 1 h each. Abbreviations: a ϭ astrocytes; n ϭ pigmented dopaminergic neuron showing neuromelanin pigmentation. Magnification, ϫ400. Scale bar ϭ 25 m. O: Immunohistochemical localization of THO in control substantia nigra. Samples were probed for THO using anti-THO (1:20) for 1 h at room temperature followed by secondary and tertiary antibodies as described in (M and N). Abbreviations: n ϭ pigmented dopaminergic neurons. Magnification, ϫ100. Scale bar ϭ 100 m. Frequency distribution of the expression of NNMT in the granular neurons of both non-PD and PD cerebella. Non-PD cerebella followed a 1:2:1 distribution of activity, with a median of 5% and a range of zero to 63%. PD cerebella were all in the high expressor (Ͼ30.1% expression) group, with a median of 95.5% and a range of 88.0-97.9%. The PD group showed significantly higher expressors than the non-PD group (p Ͻ 0.0001 using a non-parametric Mann-Whitney U-test). Grey bars ϭ non-PD; black bars ϭ PD.
Quantitation of Expression of NNMT in the Brains of PD and Non-PD Subjects
Comparison of Protein Expression (Western Blotting) and Enzyme Activity in Caudate Nucleus and Cerebellum of Patients with PD and Non-PD Subjects:
activity varied greatly between subjects, with those who had died from PD having significantly higher enzyme activity than non-PD subjects (p ϭ 0.03 for caudate nucleus, p ϭ 0.029 for cerebellum using the Mann-Whitney U non-parametric test). The levels of NNMT protein expression in subjects who had died from PD was significantly higher than non-PD subjects (p ϭ 0.0326 for caudate nucleus, p ϭ 0.0415 for cerebellum using the Mann-Whitney U non-parametric test).
Comparison of Protein Expression (Immunohistochemistry) in Cerebellum of Subjects with PD and Non-PD Subjects:
The percentage of granular cells expressing NNMT in control brains ranged from zero to 63%, with a median of 5%. Assignment of results into 3 arbitrary groups: zero; Ͼ0-30%; and Ͼ30% gave the distribution shown in Figure 5 . This distribution in the control group is similar to the 1:2:1 distribution of the level of NNMT protein expression seen in normal human liver samples (11) . The PD group was comprised entirely of high expressors (Ͼ30.1% of granular cells expresssing the protein), with a median of 95.5% and range of 88%-97.9%. Statistical analysis of the PD and non-PD groups using a two-tailed non-parametric Mann-Whitney U-test showed that the 2 groups were highly significantly different (p Ͻ 0.0001). There was no significant difference between the counting of the 2 investigators, the average difference of the means being 2% with SD of 2.3%.
There were no significant differences between PD and non-PD subjects for postmortem interval, pH of cerebellum, and age at death. No significant trend was observed between the level of NNMT expression in the cerebellum and any of the above parameters in PD subjects (data not shown). One significant trend was found in that the percentage of granular cells expressing NNMT was inversely correlated with disease duration (p ϭ 0.03, r ϭ Ϫ0.73 using Spearman rank correlation analysis).
Comparison of NNMT Expression in the Substantia Nigra of PD and Non-PD Subjects: As seen in this study, expression of NNMT was limited to dopaminergic neurons, identified by morphology and the presence of neuromelanin. Significantly fewer dopaminergic neurons per unit area were seen in the PD tissue samples than in non-PD cases (7.79 control, 3.42 PD; p ϭ 0.004 using the Student t-test), although the percentage of neurons expressing NNMT was not significantly different in the 2 groups. In sections counterstained with propidium iodide many more glial cell nuclei were evident in PD samples compared with the numbers in non-PD tissue.
DISCUSSION
Characterization of NNMT Expression and Antibody Specificity
In order to determine whether NNMT may be linked with the occurrence of PD, we began by determining the expression of NNMT in normal brain tissue using a combination of Northern blotting, Western blotting, immunohistochemistry, and activity assay. The specificity of the antibody used in 2 of these techniques, which previously had been shown to precipitate human liver NNMT activity specifically, was further confirmed by its failure to detect NNMT activity in the renal cortex, a tissue region known not to exhibit enzymic activity (18) , and its specific localization of NNMT immunoreactivity in the periportal region of liver. Using this approach, we have demonstrated that NNMT is differentially expressed regionally in the brain and expression occurs only in neurons. This is not unique, as many enzymes have been shown to have distinct regional distributions (20) (21) (22) . Non-uniform distribution may have functional significance and could represent regional requirements for either 1-methylnicotinamide or clearance of the parent compound.
Use of Extra-Substantia Nigra Tissue for Assessing NNMT Expression in PD
The use of substantia nigra tissue in studies of PD such as this is complicated by the reduction in the number of pigmented dopaminergic neurons present due to the degeneration process of the disease. Thus, in the case of an enzyme chiefly expressed in neurons, there could be a reduction in its expression simply because of the death of neurons rather than any specific effect on gene regulation. We clearly show in the substantia nigra of subjects who did not have PD that NNMT is expressed in the dopaminergic neurons and neurons of the third nerve. The enzyme is not limited to the cell body, but axonal transport of NNMT occurs. These are neurons that die in PD, and our results show the near absence of these cells in PD brain sections. Thus, the substantia nigra was considered not to be a useful tissue to study because the brain samples could only be obtained from patients at the endstage of the disease when neuronal destruction was at a maximum. Therefore, the use of extra-substantia nigra tissues, namely the cerebellum and caudate nucleus, a component of the basal ganglia, which are not strongly associated with the neurodegenerative processes in PD, would seem more appropriate to investigate levels of specific protein expression. Furthermore, in this study these regions were shown to have low levels of NNMT mRNA. In view of our starting hypothesis that PD was associated with increased levels, these regions were deemed useful because it would be relatively easy to detect an increase starting from a low normal baseline. Our results clearly demonstrated that there were significantly higher levels of NNMT in these brain regions in PD patients compared with the same regions in control brains. This was confirmed using 3 separate techniques, a finding that was not apparent from using substantia nigra tissue. It might be argued that, because caudate nucleus contains projections from dopaminergic neurons of the substantia nigra, and we demonstrated NNMT in these projections, there should be lower levels of NNMT in this region of the brain in PD subjects. However, the contribution to total caudate nucleus NNMT of the protein in these projections is minimal. Therefore, this did not influence the findings of the Western blotting and activity assays.
Comparison of NNMT Expression in Non-Parkinsonian and Parkinsonian Cerebellum
The findings of elevated levels of NNMT in specific, unaffected brain regions of PD sufferers is in accord with the findings of Matsubara et al (23) , who found increased levels of NNMT in the cerebrospinal fluid of parkinsonian patients. The higher levels of NNMT expression in PD cerebella may be due to either (a) differences in the genetically determined levels of constitutive expression, (b) linked to the onset of disease, or (c) secondary factors such as the effects of drug therapy. Furthermore, it should be borne in mind that the numbers of subjects studied are quite small, although these represent a major proportion of the available tissue from 1 major brain bank in which 3 types of investigation (SDS-PAGE/Western blotting, immunohistochemistry, and enzymic activity determination) could be carried out. This therefore suggests that a larger scale investigation is required. Notwithstanding these caveats, the significant inverse correlation between NNMT expression in the cerebellum and disease duration is suggestive of a causal link between enzyme and disease.
The assertion that levels of NNMT expression are higher in PD compared with levels in tissue from control subjects raises the questions of what is meant by a control subject and how closely do these levels represent the vivo situation in health, given that all the subjects were, of course, dead. None of the control subjects died of cancer and, therefore, did not receive cytotoxic chemotherapy that might have grossly disrupted cellular protein synthesis. The nearest answer to the second question was sought in the comparison of NNMT expression in the cerebellum of these control subjects with that seen in the livers of young healthy adults dying violent deaths in road traffic accidents (RTAs) and whose livers were rapidly removed for transplantation (11) . This latter was considered to represent the nearest to the normal in vivo situation it is possible to approach with human subjects. Both groups have levels of expression that could be represented as having a 1:2:1 distribution. Furthermore, the low and intermediate expression group had levels that were not greatly dissimilar, whereas the high expressor groups had well separated from the other two. Thus both the levels in the RTA liver group and the control cerebella reported here had similar distributions to the large population study reported by Rini et al (10) . Therefore, our claim that our control data represent the situation in the normal human brain is not without foundation and the same genetic factor responsible for determining liver activity appears to operate in the brain also.
Despite the above reservations on the effects of treatment, particularly bearing in mind that NNMT is an inducible enzyme (11) , it is worthwhile considering how genetically determined high levels of NNMT expression might be related to the onset of disease. Two main reasons can be postulated: (i) the production of toxic methylpyridinium ions and (ii) reduced substrate availability for Complex I. In addition, sub-optimal levels of vitamin B3 may promote apoptosis because nicotinamide was been shown to inhibit apoptosis induced by tertiary butylhydroperoxide (24) and methyl-phenyl-tetrahydropyridine (MPTP) (25) .
Increased Methylpyridinium Ion Analogues
As previously described, NNMT, in addition to metabolizing nicotinamide, metabolizes structurally related compounds. For example, 4-phenylpyridine, found in low amounts in tea and green leafy vegetables, can be converted to MPP ϩ by NNMT (12) . Once formed within the brain, methylpyridinium compounds can migrate to any region where they may be taken up by the dopaminergic reuptake system of dopaminergic neurons. The pigmented neurons of the substantia nigra are particularly susceptible to this due of the high levels of neuromelanin that they contain because of adsorption to neuromelanin. Thus, over a long period of time a toxic dose could build up, leading to neurodegeneration and the onset of PD. In addition, NNMT can convert distant structural analogues of endogenous origin, e.g. ß-carbolines and tetrahydroisoquinolines, to pyridinium derivatives. Increased enzymic N-methylation of such compounds in PD has been reported (26, 27) , although what the relationship between NNMT and the enzyme(s) that methylates ß-carbolines and tetrahydroisoquinolines remains to be elucidated, although Gearhart et al postulated that the methylation of all 3 classes of compounds could be brought about by the same entity (28) .
Complex I Activity
NADH is the electron donor for Complex I oxidation of glutamate and pyruvate that forms 1 of the 2 starting points of the electron transport chain of mitochondrial oxidative phosphorylation. Reduced Complex I activity has been shown to be linked with several neurological diseases such as tardive dyskinesia (29) , Leigh syndrome (30) , and PD (31, 32) , and overt vitamin B3 deficiency causes neurological pathology (33, 34) . The recent elucidation of the role of parkin in the predominantly Japanese form of familial PD also re-emphasizes the potential role of energy deficiency in the etiology of sporadic PD (35, 36) . The absence of Lewy bodies in this form of familial PD is attributed to the inability of the mutant parkin to bring about ␣-synuclein ubiquitinylation. Clearly in sporadic PD ␣-synuclein is ubiquitinylated. Because it forms a major component of Lewy bodies (37, 38) , ␣-synuclein in sporadic PD is not undergoing proteasomal catabolism efficiently. Numerous studies have shown that ␣-synuclein, parkin, and ubiquitin terminal hydroxylase mutations are rare, if ever, causes of sporadic PD (39) (40) (41) ; hence mutation of these genes would appear an unlikely cause of inefficient ␣-synuclein catabolism. Mutations of genes whose products go to form the proteasome are a possible but somewhat unexplored cause, as is relative deficiency of the Complex 1 substrate-NADH. Although tryptophan metabolism can yield vitamin B3, this is a very inefficient source and Western diets tend to have barely adequate levels of intake. It would seem logical, therefore, that an elevated level of NNMT would place higher dietary requirements for both vitamin B3 and tryptophan, which, if not fulfilled, may lead to a reduction in available NADH and thence to decreased Complex I activity. Thus, a subsequent insult that further reduced Complex I activity could then lead to oxidative stress and its further consequences, particularly in cells such as the dopaminergic neurons. Because of such considerations NADH therapy has been proposed as a treatment for PD. Pilot studies gave mixed results but no large-scale multicenter trial has been carried out (42) .
Some of the effects of the genetically high level of NNMT could be offset by high dietary intake of vitamin B3, although nicotinamide induces NNMT expression in the liver and possibly other tissues (43) . High nicotinamide levels give rise to increased choline synthesis (44) (45) (46) (47) , although the effect on choline levels is marginal. Nevertheless, this may not be beneficial in brains that are developing PD.
In conclusion, NNMT is a neuronally expressed enzyme with a wide substrate profile. In the liver, levels of activity are strongly genetically determined. Depending on substrate exposure, the products of its activity may be either directly toxic to Complex I or cause a diminution of available levels of the essential electron donor for this complex's action. In view of the fact that reduced Complex I activity is one of the cardinal biochemical features of PD, the findings of high levels of this enzyme in the cerebella and caudate nucleus of PD patients, and the inverse correlation of enzyme expression in the cerebellum with disease duration suggest that this enzyme may be one link between the genetic and environmental factors in the etiology of PD.
